Crossmark

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

Crossref DOI link: https://doi.org/10.1038/s41436-021-01287-7

Published Print: 2021-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Savarirayan, Ravi http://orcid.org/0000-0002-5105-8427
Tofts, Louise

Irving, Melita

Wilcox, William R.

Bacino, Carlos A.

Hoover-Fong, Julie

Font, Rosendo Ullot

Harmatz, Paul

Rutsch, Frank

Bober, Michael B.

Polgreen, Lynda E.

Ginebreda, Ignacio

Mohnike, Klaus

Charrow, Joel

Hoernschemeyer, Daniel

Ozono, Keiichi

Alanay, Yasemin

Arundel, Paul

Kotani, Yumiko

Yasui, Natsuo

White, Klane K.

Saal, Howard M.

Leiva-Gea, Antonio

Luna-González, Felipe

Mochizuki, Hiroshi

Basel, Donald

Porco, Dania M.

Jayaram, Kala

Fisheleva, Elena

Huntsman-Labed, Alice

Day, Jonathan R.S.
License Information

Text and Data Mining valid from 2021-12-01

Version of Record valid from 2021-08-02
More Information

This article is maintained by: Elsevier

Article Title: Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

Journal Title: Genetics in Medicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1038/s41436-021-01287-7

Content Type: article

Copyright: © 2021, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics

Document is current

Any future updates will be listed below